# ENDRA Life Sciences Inc.: Form 10-Q for the period ended Sep 30, 2017

- Company: [ENDRA Life Sciences Inc.](/companies/ndra.md) (CIK 1681682)
- Form: 10-Q
- Filed: 2017-11-14
- Accepted by EDGAR: Nov 14, 2017, 16:20 ET
- Period: 2017-09-30
- Accession: 0001654954-17-010633
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1681682/000165495417010633/ndra_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1681682/000165495417010633/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Gross profit | 3 months, 2017-07-01 to 2017-09-30 | $168.7k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2017-01-01 to 2017-09-30 | $175.1k | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-07-01 to 2017-09-30 | $300.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2017-01-01 to 2017-09-30 | $571.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-07-01 to 2017-09-30 | −$910.9k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-01-01 to 2017-09-30 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-07-01 to 2017-09-30 | $2.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-01-01 to 2017-09-30 | $752.8k | us-gaap:InterestExpense |
| Income tax | 3 months, 2017-07-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2017-01-01 to 2017-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-07-01 to 2017-09-30 | −$908.9k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2017-01-01 to 2017-09-30 | −$3.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | −$0.23 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2017-01-01 to 2017-09-30 | −$1.30 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2017-01-01 to 2017-09-30 | −$1.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2017-01-01 to 2017-09-30 | $7.9k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-09-30 | $7.0m | us-gaap:Cash |
| Current assets | at 2017-09-30 | $7.2m | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $7.5m | us-gaap:Assets |
| Current liabilities | at 2017-09-30 | $312.0k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-09-30 | $312.0k | us-gaap:Liabilities |
| Shareholders' equity | at 2017-09-30 | $7.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 27,921 characters.

### Forward-Looking Statements

As used in this Quarterly Report on Form 10-Q (this “Form 10-Q”), unless the context otherwise requires, the terms “we,” “us,” “our,” “ENDRA” and the “Company” refer to ENDRA Life Sciences Inc., a Delaware corporation. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our historical financial statements and related notes thereto in this Form 10-Q. This Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or other comparable terms. All statements other than statements of historical facts included in this Form 10-Q regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expectations for revenues, cash flows and financial performance, the anticipated results of our development efforts and the timing for receipt of required regulatory approvals and product launches. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to develop a commercially feasible technology; receipt of necessary regulatory approvals; our ability to find and maintain development partners, market acceptance of our technology, the amount and nature of competition in our industry; our ability to protect our intellectual property; and the other risks and uncertainties described in the Risk Factors section of our Quarterly Report on Form 10-Q for the period ended March 31, 2017, as filed with the SEC on June 21, 2017, and in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of this Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

### Overview

We have commercialized an enhanced ultrasound technology for the pre-clinical research market and are leveraging that expertise to develop technology for increasing the capabilities of clinical diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography (“CT”) and magnetic resonance imaging (“MRI”) technology is unavailable or impractical.

Since 2010, we have marketed and sold our Nexus 128 system, which combines light-based thermoacoustics and ultrasound, to address the imaging needs of researchers studying disease models in pre-clinical applications. Sales of the Nexus 128 system were approximately $1.4 million in 2015 and $515,000 in 2016. Our Nexus 128 system is used in a number of leading global academic research centers, including Stanford University, The University of Michigan, Shanghai Jiao Tong University, and Purdue University. We expect to continue to sell our Nexus 128 system to maintain a base level of revenue, but believe the market potential for our clinical systems is much higher.

Building on our expertise in thermoacoustics, we developed a next-generation technology platform — Thermo Acoustic Enhanced Ultrasound, or TAEUS — which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of a number of significant medical conditions that currently require the use of expensive CT or MRI imaging or where imaging is not practical using existing technology.

Unlike the near-infrared light pulses used in our Nexus 128 system, our TAEUS technology uses radio frequency (“RF”) pulses to stimulate tissues, using a small fraction of the energy transmitted into the body during an MRI scan. The use of RF energy allows our TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals, which are detected by an external ultrasound receiver and a digital acquisition system that is part of the TAEUS system. The detected ultrasound is processed into images using our proprietary algorithms and overlaid in real time onto conventional gray-scale ultrasound images.

We expect that the first-generation TAEUS application will be a standalone ultrasound accessory designed to cost-effectively quantify fat in the liver and stage progression of non-alcoholic fatty liver disease, or (“NAFLD”), which can only be achieved today with impractical surgical biopsies or MRI scans. Subsequent TAEUS offerings are expected to be implemented via a second generation hardware platform that can run multiple clinical software applications that we will offer TAEUS users for a one-time licensing fee – adding ongoing customer value to the TAEUS platform and a growing software revenue stream for our Company.

Each of our TAEUS platform applications will require regulatory approvals before we are able to sell or license the application. Based on certain factors, such as the installed base of ultrasound systems, availability of other imaging technologies, such as CT and MRI, economic strength and applicable regulatory requirements, we intend to seek initial approval of our applications for sale in the European Union, followed by the United States and China.

In April 2016, we entered into a Collaborative Research Agreement with General Electric Company, acting through its GE Healthcare business unit and the GE Global Research Center (collectively, “GE Healthcare”). Under the terms of the agreement, GE Healthcare has agreed to assist us in our efforts to commercialize our TAEUS technology for use in a fatty liver application by, among other things, providing equipment and technical advice, and facilitating introductions to GE Healthcare clinical ultrasound customers. In return for this assistance, we have agreed to afford GE Healthcare certain rights of first offer with respect to manufacturing and licensing rights for the target application. More specifically, we have agreed that, prior to commercially releasing our NAFLD TAEUS application, we will offer to negotiate an exclusive ultrasound manufacturer relationship with GE Healthcare for a period of at least one year of commercial sales. The commercial sales would involve, within our sole discretion, either our Company commercially selling GE Healthcare ultrasound systems as the exclusive ultrasound system with our TAEUS fatty liver application embedded, or GE Healthcare being the exclusive ultrasound manufacturer to sell ultrasound systems with our TAEUS fatty liver application embedded. The agreement is subject to termination by either party upon not less than 60 days’ notice. On April 21, 2017, we and GE Healthcare entered into an amendment to our agreement, extending its term by one year to April 22, 2018.

Subsequent to the period ended September 30, 2017 we announced that we have partnered with StarFish Medical (“StarFish”), Canada’s largest medical device development and contract manufacturing company, and CriTech Research Inc. (“CriTech”), a U.S. firm specializing in medical device software development, to commence productization of our TAEUS device targeting Non-Alcoholic Fatty Liver Disease (NAFLD). The agreements call for StarFish and CriTech to provide us with the specialized engineering resources necessary to translate our current prototype TAEUS device into a clinical product meeting CE regulatory requirements required for commercial launch in the European Union, targeted for 2018, followed by FDA submission for the U.S. market. StarFish is an ISO 13485 certified product engineering firm with offices in Victoria, British Columbia and Toronto, Ontario dedicated to the medical device and life science marketplace. CriTech Research Inc., headquartered in Saline, Michigan, has more than 20 years of experience in the development and testing of safety-critical software for medical devices. CriTech is certified to ISO13485 and ISO 9001 for software development.

### Financial Operations Overview

#### Revenue

To date our revenue has been generated by the placement and sale of our Nexus 128 system for use in pre-clinical applications.

#### Cost of Goods Sold

Our cost of goods sold is related to our direct costs associated with the development and shipment of our thermoacoustic imaging systems placed in pre-clinical settings.

#### Research and Development Expenses

Our research and development expenses primarily include wages, fees and equipment for the development of our TAEUS technology platform and our proposed applications. Additionally, we incur certain costs associated with the protection of our products and inventions through a combination of patents, licenses, applications and disclosures.

#### Sales and Marketing Expenses

Sales and marketing expenses consist primarily of advertising, marketing and consulting expenses and headcount. Currently, our marketing efforts for our pre-clinical business are through distributors in China, the European Union, Australia, Korea and the United Kingdom, our website, and attendance of key industry meetings. In connection with the commercialization of our TAEUS applications, we expect to build a small sales and marketing team to train and support global ultrasound distributors, as well as execute traditional marketing activities such as promotional materials, electronic media and participation in industry conferences.

#### General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related expenses for our management and personnel, and professional fees, such as accounting, consulting and legal.

### Critical Accounting Policies and Estimates

#### Use of Estimates

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Management makes estimates that affect certain accounts including deferred income tax assets, accrued expenses, fair value of equity instruments and reserves for any other commitments or contingencies. Any adjustments applied to estimates are recognized in the period in which such adjustments are determined.

#### Share-based Compensation

Our 2016 Omnibus Incentive Plan, which has been approved by our board of directors, permits the grant of share options and shares to our employees, consultants and non-employee members of our board of directors for up to 1,345,074 shares of common stock. We record share-based compensation in accordance with the provisions of the Share-based Compensation Topic of the FASB Codification. The guidance requires the use of option-pricing models that require the input of highly subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option valuation model which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, and future dividends, and the resulting charge is expensed using the straight-line attribution method over the vesting period.

Stock compensation expense recognized during the period is based on the value of share-based awards that were expected to vest during the period adjusted for estimated forfeitures. The estimated fair value of grants of stock options and warrants to non-employees is charged to expense, if applicable, in the financial statements.

#### Recent Accounting Pronouncements

See Note 2 of the financial statements for a discussion of recently issued accounting standards.

### Results of Operations

### Three Months Ended September 30, 2017 and 2016

#### Revenues

We had revenue of $287,000 for the three months ended September 30, 2017, as compared to $0 for the three months ended September 30, 2016. The revenue was a result of the sale of one of our Nexus 128 laboratory imaging systems in the three months ended September 30, 2017.

#### Cost of Goods Sold

Cost of goods sold was $118,270 and $0 for the three months ended September 30, 2017 and 2016, respectively. The cost of goods sold was a result of direct costs associated with the sale of one of our Nexus 128 laboratory imaging systems. Gross margin was approximately 59% for the three months ended September 30, 2017.

#### Research and Development

Research and development expenses were $300,527 for the three months ended September 30, 2017, as compared to $137,540 for the three months ended September 30, 2016, an increase of $162,987, or 119%. The costs include primarily wages, fees and equipment for the development of our TAEUS product line. Research and development expenses increased from the same period for the prior year due primarily to increased wages and employment related expenses.

#### Sales and Marketing

Sales and marketing expenses were $47,375 for the three months ended September 30, 2017, as compared to $16,040 for the three months ended September 30, 2016, an increase of $31,335, or 195%. The increase was primarily due to commissions paid on the sale of our Nexus 128 system. Currently our marketing efforts for our pre-clinical business are coordinated and led by a recently hired full-time employee who is responsible for the sales of our Nexus 128 systems, as well as coordinating sales through distributors in China, the European Union, Australia and the United Kingdom, our website and attendance of key industry meetings. Our future clinical business will involve hiring and training additional staff to support our sales efforts. As we seek to complete the development and commercialization of our TAEUS applications, we intend to build a small sales and marketing team to train and support global ultrasound distributors, as well as execute traditional marketing activities such as promotional materials, electronic media and participation in industry conferences.

#### General and Administrative

Our general and administrative expenses for the three months ended September 30, 2017 were $731,763, an increase of $280,533, or 62%, compared to $451,530 for the three months ended September 30, 2016. General and administrative expenses increased due to an increase in headcount and related operations after our IPO in May 2017. Our wage and related expenses for the three months ended September 30, 2017 were $376,810, compared to $231,918 for the three months ended September 30, 2016. Wage and related expenses in the three month period ended September 30, 2017 included $183,473 of stock compensation expense related to the issuance and vesting of options, compared to $103,483 of stock compensation expense for the same period in 2016. Our professional fees for the three months ended September 30, 2017 were $201,733, compared to $149,454 for the three months ended September 30, 2016.

#### Net loss

As a result of the foregoing, for the three months ended September 30, 2017, we recorded a net loss of $908,908 compared to a net loss of $977,898 for the three months ended September 30, 2016.

### Nine months Ended September 30, 2017 and 2016

#### Revenues

We had revenue of $344,772 for the nine months ended September 30, 2017, as compared to $0 for the nine months ended September 30, 2016. The revenue was a result of the sale of one of our Nexus 128 laboratory imaging systems, and product service fees generated from our installed base of Nexus 128 laboratory imaging systems, for the nine months ended September 30, 2017.

#### Cost of Goods Sold

Cost of goods sold was $169,697 and $0 for the nine months ended September 30, 2017 and 2016, respectively. The cost of goods sold was a result of direct costs associated with the sale of one of our Nexus 128 laboratory imaging systems, and product service materials required for the service of a unit in our installed base of Nexus 128 laboratory imaging systems. Gross margin was approximately 51% for the nine months ended September 30, 2017.

#### Research and Development

Research and development expenses were $571,066 for the nine months ended September 30, 2017, as compared to $336,417 for the nine months ended September 30, 2016, an increase of $234,649, or 70%. The costs include primarily wages, fees and equipment for the development of our TAEUS product line. Research and development expenses increased from the same period for the prior year due primarily to increased wages and employment related expenses.

#### Sales and Marketing

Sales and marketing expenses were $55,403 for the nine months ended September 30, 2017, as compared to $26,197 for the nine months ended September 30, 2016, an increase of $29,206, or 111%. The increase was primarily due to commissions paid on the sale of our Nexus 128 system. Currently our marketing efforts for our pre-clinical business are through distributors in China, the European Union, Australia and the United Kingdom, our website and attendance of key industry meetings. Our future clinical business will involve hiring and training additional staff to support our sales efforts. As we seek to complete the development and commercialization of our TAEUS applications, we intend to build a small sales and marketing team to train and support global ultrasound distributors, as well as execute traditional marketing activities such as promotional materials, electronic media and participation in industry conferences.

#### General and Administrative

Our general and administrative expenses for the nine months ended September 30, 2017 were $1,878,093, an increase of $767,830, or 69%, compared to $1,110,263 for the nine months ended September 30, 2016. General and administrative expenses increased due to an increase in headcount and one-time expenses related to the IPO. Our wage and related expenses for the nine months ended September 30, 2017 were $876,016, compared to $549,429 for the nine months ended September 30, 2016. Wage and related expenses in the nine month period ended September 30, 2017 included $422,698 of stock compensation expense related to the issuance and vesting of options, compared to $172,723 of stock compensation expense for the same period in 2016. Our professional fees for the nine months ended September 30, 2017 were $688,649, compared to $384,399 for the nine months ended September 30, 2016.

#### Net loss

As a result of the foregoing, for the nine months ended September 30, 2017, we recorded a net loss of $3,082,322 compared to a net loss of $2,086,490 for the nine months ended September 30, 2016.

### Liquidity and Capital Resources

To date, we have generated only limited revenues from sales of our Nexus 128 system. We have funded our operations to date through private and public sales of our securities. As of September 30, 2017, we had $6,977,462 in cash. In May 2017, we completed the IPO, raising net proceeds of approximately $8.6 million after deducting offering expenses of approximately $773,000 in underwriting discounts, commissions and expenses and approximately $297,000 in offering expenses payable by the Company.

We believe that cash on hand at September 30, 2017 and other potential sources of cash, including revenues we generate from sales of our Nexus 128 system, will be sufficient to fund our current operations into the fourth quarter of 2018. We plan to explore potential financing options that may be available to us, including additional sales of our common stock. However, we have no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all. If the Company is unable to obtain additional financing in a timely fashion and on terms acceptable to the Company, the Company’s financial condition and results of operations may be materially adversely affected and the Company may not be able to continue operations or execute its commercialization plan.

The financial statements included in this Form 10-Q have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, during the nine months ended September 30, 2017, the Company incurred net losses of $3,082,322, and used cash in operations of $1,925,329. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the financial statements. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

### Operating Activities

During the nine months ended September 30, 2017, the Company used $1,925,329 of cash in operating activities primarily as a result of its net loss of $3,082,322, offset by amortization of discount of convertible debt of $711,472, share-based compensation of $600,514, $46,121 in depreciation and amortization expenses, and net changes in operating assets and liabilities of $(202,594).

During the nine months ended September 30, 2016, the Company used $769,459 of cash in operating activities primarily as a result of its net loss of $2,086,490, offset in part by net changes in operating assets and liabilities of $(114,513), $48,612 in depreciation and amortization expense, $199,723 in non-cash stock compensation expense, amortization of discount of convertible debt of $561,812, and additional warrants of $5,823 issued during the warrant exchange program, pursuant to which the Company issued warrants to participating warrant holders in exchange for such participants’ exercising their then-held warrants.

### Investing Activities

During the nine months ended September 30, 2017, the Company used $7,862 in investing activities related to purchase of equipment. There were no investing activities for the nine months ended September 30, 2016.

### Financing Activities

During the nine months ended September 30, 2017, financing activities provided $8,590,700 in proceeds from the IPO and $225,000 in proceeds from convertible notes. The Company used $50,000 in repayments of notes payable.

During the nine months ended September 30, 2016, financing activities provided $1,441,448, including $5,000 from common stock issued for cash, $50,000 in proceeds from notes payable, and $1,386,448 in proceeds from convertible notes.

### Funding Requirements

We have not completed development of our TAEUS technology platform applications. We expect to continue to incur significant expenses for the foreseeable future. We anticipate that our expenses will increase substantially as we:

advance the engineering design and development of our NAFLD TAEUS application;

prepare applications required for marketing approval of our NAFLD TAEUS application in the European Union and the United States;

seek to hire a small internal marketing team to engage and support channel partners and clinical customers for our NAFLD TAEUS application;

commence marketing of our NAFLD TAEUS application;

advance development of our other TAEUS applications; and

add operational, financial and management information systems and personnel, including personnel to support our product development, planned commercialization efforts and our operation as a public company.

We believe that our existing cash, taking into account the net proceeds of our IPO, will be sufficient for us to fund the development and regulatory approval and to prepare for the commercialization of our NAFLD TAEUS application in the European Union. It is possible that we will not achieve the progress that we expect because the actual costs and timing of completing the development and regulatory approvals for a new medical device are difficult to predict and are subject to substantial risks and delays. We have no committed external sources of funds. We do not expect that our existing cash will be sufficient for us to complete the commercialization of our NAFLD TAEUS application or to complete the development of any other TAEUS application and we will need to raise substantial additional capital for those purposes. As a result, we will need to finance our future cash needs through public or private equity offerings, debt financings, corporate collaboration and licensing arrangements or other financing alternatives. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the section of our Quarterly Report on Form 10-Q for the period ended March 31, 2017 entitled “Risk Factors” and elsewhere in this Form 10-Q. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.

Until we can generate a sufficient amount of revenue from our TAEUS platform applications, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or applications or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.

### Off Balance Sheet Transactions

We do not have any off balance sheet transactions.

## Market risk

As filed, 183 characters.

The information required by Item 3 is not required to be provided by issuers that satisfy the definition of “smaller reporting company” under Securities and Exchange Commission rules.

## Controls and procedures

As filed, 2,789 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Form 10-Q, management performed, with the participation of our principal executive officer and principal financial officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2017, our disclosure controls and procedures were not effective.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We identified the following material weakness as of September 30, 2017: insufficient personnel resources within the accounting function to segregate the duties over financial transaction processing and reporting.

To remediate our internal control weaknesses, management intends to implement the following measures, as finances allow:

We will add sufficient accounting personnel or outside consultants to properly segregate duties and to effect a timely, accurate preparation of the financial statements.

Upon the hiring of additional accounting personnel or outside consultants, we will develop and maintain adequate written accounting policies and procedures.

The additional hiring is contingent upon our efforts to obtain additional funding and the results of our operations. Management expects to secure funds in the coming fiscal year but provides no assurances that it will be able to do so.

### Changes in Internal Control over Financial Reporting

There was no change to our internal controls or in other factors that could affect these controls during the three month period ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, our management is currently seeking resolutions to improve our controls and procedures in an effort to remediate the deficiency described above.

## Risk factors

As filed, 590 characters.

In addition to the other information set forth in this report, you should carefully consider the factors discussed under “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended March 31, 2017, as filed with the Securities and Exchange Commission on June 21, 2017. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by any forward-looking statements contained in this report.

Filed Nov 14, 2017.
Source: SEC EDGAR, the filing index for accession 0001654954-17-010633. Last ingested by Listed: Nov 10, 2026, 17:03 ET. No prices; not investment advice.
